| Media release Ypsomed shares Q3 2025/26 update in new quarterly CEO statement series Burgdorf, 9 January 2026, 07:00 a.m. – CEO Simon Michel presents Ypsomed's (SIX: YPSN) strategic direction and key highlights for the third quarter of the 2025/26 financial year. The video marks the first episode of a new quarterly CEO update series, offering regular insights into strategic progress and market development alongside Ypsomed's regular financial reporting. 
Ypsomed reached multiple strategic milestones in Q3 2025/26: - Three new product platforms were launched, and the fully recyclable autoinjector YpsoLoop won the prestigious CPHI Innovation Award.
- Ypsomed announced the new clinical excellence program "Clear-to-Clinic", de-risking and accelerating clinical trials for pharma and biotech clients.
- Five drugs launched in Ypsomed devices in Q3 2025/26.
- The manufacturing expansion is well underway; in the US Ypsomed acquired land and building for the new Holly Springs site and in China first batches were delivered to local customers.
Ypsomed will engage with stakeholders at various events over the coming months to further discuss strategic priorities, key business development milestones, and market trends, including: - J.P. Morgan Healthcare Conference, San Francisco, 12–15 January 2026
- KeyBanc Annual Healthcare Forum, Virtual, 17–18 March 2026
- Media and Analyst Conference for the 2025/26 full-year results, Zurich, 20 May 2026
- UBS Zurich Roadshow, Zurich, 22 May 2026
- Deutsche Bank Access European Champions Conference, Frankfurt am Main, 26–27 May 2026
- Oddo BHF Swiss Equities Conference, Interlaken, 9–10 June 2026
- UBS Best of Switzerland Conference, Wolfsberg, 22–24 September 2026
|
Ypsomed Group Ypsomed is the leading developer and manufacturer of injection systems for the self-administration of liquid medication. As the reliable partner of pharmaceutical and biotech companies for more than 40 years, Ypsomed provides tailored selfcare solutions to meet specific needs. Backed by a proven track record, Ypsomed offers the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices. Delivered with best-in-class execution and ready to integrate with digital health services, these solutions help simplify therapy and improve the quality of life for millions of people living with chronic conditions. Ypsomed is headquartered in Burgdorf, Switzerland, and operates a global network of manufacturing facilities. More than 2,000 employees worldwide are committed every day to making selfcare simpler and easier. |
|
| |
|
|
